InnoCare Pharma (09969) announced its interim results, with adjusted profits of approximately 277 million yuan, marking a year-on-year turnaround from losses to profits.

InnoCare Pharma (09969) announced its interim results for 2026, reporting revenues of approximately 1.137 billion yuan, a year-on-year increase of 55.46%; adjusted profit of approximately 277 million yuan, returning to profitability compared to the previous year; and net profit attributable to parent company owners of about 246 million yuan, also a turnaround from losses year-on-year. The announcement stated that the revenue growth was mainly due to strong increases in drug sales and milestone delivery achievements from its collaboration with Zenas BioPharma, Inc. (NASDAQ: ZBIO). Drug sales rose 43.2% from 641 million yuan in the six months ending June 30, 2025, to 918 million yuan, primarily driven by the continued strong growth of Orelabrutinib and the new launches of Tazemetostat and Surufatinib. During the reporting period, InnoCare Pharma further advanced its multi-product, multi-area strategy, with contributions in the fields of hematological oncology, autoimmune diseases, and solid tumors continuing to expand. Several assets have either made progress towards or have achieved key regulatory and clinical milestones, laying a solid foundation for sustained long-term growth. With multiple products commercialized or regulatory submissions impending, InnoCare Pharma has entered a new phase of diversified growth, enhancing profit predictability while expanding its global business footprint. With rigorous execution and an expanded product portfolio, the company possesses ample advantages for sustainable value creation.